TCRX Q1 2022 Earnings — TScan Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TCRXTScan Therapeutics, Inc.

$69M

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M+49.0% YoY

Gross Profit

-$12M-386.3% margin

Operating Income

-$16M-535.0% margin

Net Income

-$16M-534.8% margin

EPS (Diluted)

$-0.67

QoQ Revenue Growth

+5.9%

Cash Flow

Operating Cash Flow

-$20M

Free Cash Flow

-$21M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$168M

Total Liabilities

$23M

Stockholders' Equity

$146M

Cash & Equivalents

$141M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$2M	+49.0%
Gross Profit	-$12M	-$5M	-119.7%
Operating Income	-$16M	-$8M	-104.1%
Net Income	-$16M	-$8M	-104.2%